Imvax to Present at Two Investor Conferences in May
PHILADELPHIA--(BUSINESS WIRE)--Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced that Chief Executive Officer John P. Furey will be presenting at the following upcoming investor conferences:
2022 RBC Capital Markets Global Healthcare Conference
Date: May 18, 2022 Time: 2:05 p.m. ET
Location: New York City, NY
UBS Global Healthcare Conference 2022
Date: May 24, 2022 Time: 12:15 p.m. ET
Location: New York City, NY
About Imvax, Inc.
Imvax is a clinical-stage biotechnology company with a unique platform technology focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax’s portfolio includes several programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax’s most advanced program is IGV-001 for the treatment of glioblastoma. Imvax is headquartered in Philadelphia, PA. For additional information, please visit www.imvax.com.
Contacts
Media contact:
Lisa Raffensperger
lisa@tenbridgecommunications.com
(617) 903-8783
Editor Details
-
Company:
- Businesswire
